The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.

about

Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?

P2860

Q52595390-8E2E500A-8B89-4202-87C6-E2D056C2FB2D Q55103792-EDE282B4-EDEC-4341-902B-9FDEA99D3DA3

P2860

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.

Item

http://www.wikidata.org/entity/Q47725954

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.

@en

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.

@nl

type

Item

label

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.

@en

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.

@nl

prefLabel

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.

@en

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.

@nl

P1476

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.

@en

P2093

Anna Ianza

http://www.w3.org/2001/XMLSchema#string

Daniele Generali

http://www.w3.org/2001/XMLSchema#string

Fabrizio Zanconati

http://www.w3.org/2001/XMLSchema#string

Marina Bortul

http://www.w3.org/2001/XMLSchema#string

Maurizio Scaltriti

http://www.w3.org/2001/XMLSchema#string

Silvia P Corona

http://www.w3.org/2001/XMLSchema#string

P2860

P110delta, a novel phosphoinositide 3-kinase in leukocytes

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

The phosphoinositide 3-kinase pathway

Meta-analysis in clinical trials

Statistical aspects of the analysis of data from retrospective studies of disease

Role of Akt signaling in resistance to DNA-targeted therapy

Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase

P304

4287-4292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1002/JCB.26687

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Giandomenico Roviello

Navid Sobhani

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29345357

http://www.w3.org/2001/XMLSchema#string

P932

5995110

http://www.w3.org/2001/XMLSchema#string

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.

about

P2860

P2860

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932